Robert E. Gagnon - 04 Jun 2025 Form 4 Insider Report for Bone Biologics Corp (BBLG)

Role
Director
Signature
/s/ Robert E. Gagnon
Issuer symbol
BBLG
Transactions as of
04 Jun 2025
Net transactions value
$0
Form type
4
Filing time
06 Jun 2025, 17:01:12 UTC
Previous filing
27 May 2025
Next filing
20 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Gagnon Robert E. Director C/O BONE BIOLOGICS CORP,, 2 BURLINGTON WOODS DR. SUITE 100, BURLINGTON, /s/ Robert E. Gagnon 06 Jun 2025 0001504983

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BBLG Non-Employee Stock Option Award $0 +62,894 $0.000000 62,894 04 Jun 2025 Common Stock 62,894 $0.8800 Direct F1
holding BBLG Non-Employee Stock Option 30,713 04 Jun 2025 Common Stock 30,713 $1.73 Direct F2
holding BBLG Non-Employee Stock Option 9 04 Jun 2025 Common Stock 9 $4.68 Direct F3
holding BBLG Non-Employee Stock Option 8,006 04 Jun 2025 Common Stock 8,006 $4.68 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests in four equal quarterly installments.
F2 This option was granted on 9/17/2024 and vests in four equal quarterly installments.
F3 This option is fully exercisable as of the date of this report.